Press release
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm
DelveInsight's, "Nephrotic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nephrotic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.DelveInsight's analysis indicates that over three key companies are actively engaged in developing more than three therapies for Nephrotic Syndrome.
Nephrotic Syndrome Overview:
Nephrotic Syndrome is a group of symptoms indicating impaired kidney function. Common signs include high protein levels in the urine, low protein levels in the blood, elevated blood fats or cholesterol, and swelling in different parts of the body. While it can affect anyone, it is slightly more common in men, and in children, it typically appears between ages 2 and 6.
In adults, the most frequent primary cause of nephrotic syndrome is focal segmental glomerulosclerosis (FSGS), a kidney disease that can only be definitively diagnosed through a kidney biopsy. Even with treatment, many people with FSGS may progress to kidney failure, requiring dialysis or a kidney transplant. There is also a risk that FSGS can recur after a transplant, potentially affecting the new kidney.
Download our report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Nephrotic Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nephrotic Syndrome Therapeutics Market.
Key Takeaways from the Nephrotic Syndrome Pipeline Report
*
DelveInsight's Nephrotic Syndrome pipeline report highlights a dynamic landscape with more than three active companies working to develop over three therapies for the condition.
*
In March 2025, the FDA approved scPharmaceuticals' supplemental New Drug Application (sNDA) to expand FUROSCIX (furosemide injection) for treating edema in adult patients with chronic kidney disease, including those with nephrotic syndrome. FUROSCIX, a subcutaneous furosemide injection, was previously approved for chronic heart failure and now addresses fluid overload, a serious complication in CKD patients.
*
Also in March 2025, ANI Pharmaceuticals received FDA approval for a new prefilled syringe version of Purified Cortrophin Gel (repository corticotropin injection), indicated for multiple conditions including inducing diuresis or remission of proteinuria in nephrotic syndrome, whether idiopathic or lupus-related, without uremia.
*
Key companies advancing treatments for nephrotic syndrome include GlaxoSmithKline, Goldfinch Bio, Travere Therapeutics, Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others. Promising pipeline therapies in development include Belimumab and additional candidates.
Nephrotic Syndrome Pipeline Analysis
The Nephrotic Syndrome pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Nephrotic Syndrome Market.
*
Categorizes Nephrotic Syndrome therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Nephrotic Syndrome drugs under development based on:
*
Stage of development
*
Nephrotic Syndrome Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Nephrotic Syndrome Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Nephrotic Syndrome Licensing agreements
*
Funding and investment activities supporting future Nephrotic Syndrome market advancement.
Request for a sample report @ https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Nephrotic Syndrome Emerging Drugs
*
Belimumab: GlaxoSmithKline
Nephrotic Syndrome Companies
Approximately three or more leading companies are actively developing therapies for Nephrotic Syndrome. Among these, GlaxoSmithKline has a drug candidate that has advanced to the most progressed stage of development-Phase II clinical trials.
DelveInsight's report covers around 3+ products under different phases of Nephrotic Syndrome clinical trials like
*
Nephrotic Syndrome Late stage Therapies (Phase III)
*
Nephrotic Syndrome Mid-stage Therapies (Phase II)
*
Nephrotic Syndrome Early-stage Therapies (Phase I)
*
Nephrotic Syndrome Pre-clinical and Nephrotic Syndrome Discovery stage Therapies
*
Nephrotic Syndrome Discontinued & Inactive Therapies
Nephrotic Syndrome pipeline report provides the Nephrotic Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Nephrotic Syndrome Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Nephrotic Syndrome Therapies and Key Nephrotic Syndrome Companies: Nephrotic Syndrome Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Nephrotic Syndrome Pipeline Therapeutic Assessment
- Nephrotic Syndrome Assessment by Product Type
- Nephrotic Syndrome By Stage
- Nephrotic Syndrome Assessment by Route of Administration
- Nephrotic Syndrome Assessment by Molecule Type
Download Nephrotic Syndrome Sample report to know in detail about the Nephrotic Syndrome treatment market @ Nephrotic Syndrome Therapeutic Assessment [https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Nephrotic Syndrome Current Treatment Patterns
4. Nephrotic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Nephrotic Syndrome Late-Stage Products (Phase-III)
7. Nephrotic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Nephrotic Syndrome Discontinued Products
13. Nephrotic Syndrome Product Profiles
14. Nephrotic Syndrome Key Companies
15. Nephrotic Syndrome Key Products
16. Dormant and Discontinued Products
17. Nephrotic Syndrome Unmet Needs
18. Nephrotic Syndrome Future Perspectives
19. Nephrotic Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Nephrotic Syndrome Pipeline Reports Offerings [https://www.delveinsight.com/report-store/nephrotic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nephrotic-syndrome-pipeline-analysis-2025-by-delveinsight-glaxosmithkline-goldfinch-bio-inc-travere-therapeutics-inc-aurinia-pharmaceuticals-bristolmyers-squibb-chemocentryx-synact-pharm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm here
News-ID: 4167142 • Views: …
More Releases from ABNewswire

Hepatocellular Carcinoma Clinical Trials Assessment 2025: Competitive Landscape, …
Hepatocellular Carcinoma companies are Polaris Pharmaceuticals, Sumitomo Pharma, Surface Oncology, Oxford BioTherapeutics, OriCell Therapeutics, Tarus Therapeutics, Tvardi Therapeutics, SCG Cell Therapy, AVEO Oncology, Sinocelltech, GlaxoSmithKline, Iterion Therapeutics, Array BioPharma, Beijing SyngenTech, Antengene Corporation, Shenogen Pharma, Novartis Oncology, Eutilex, SillaJen Biotherapeutics, Guangdong ProCap Zoom Biosciences, and Chugai Pharmaceutical.
(Albany, USA) According to DelveInsight's analysis, the Hepatocellular Carcinoma (HCC) pipeline Report comprises over 90+ companies developing more than 95+ drug candidates across diverse…

Ocular Hypertension Pipeline Analysis, 2025 by DelveInsight | Santen Pharmaceuti …
DelveInsight's, "Ocular Hypertension - Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Ocular Hypertension pipeline includes over 50 prominent companies actively…

Chronic Lymphocytic Leukemia Pipeline Analysis, 2025 by DelveInsight | Loxo Onco …
DelveInsight's, "Chronic Lymphocytic Leukemia (CLL) - Pipeline Insight, 2025," report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Chronic Lymphocytic Leukemia (CLL) pipeline…

Netherton Syndrome Pipeline Analysis, 2025 by DelveInsight | TenNor Therapeutics …
DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight analysis reveals that over five key companies are actively engaged…
More Releases for Nephrotic
Nephrotic Syndrome Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology as well as the Nephrotic Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Nephrotic Syndrome, offering comprehensive insights into the Nephrotic Syndrome revenue trends, prevalence, and treatment landscape. The…
Nephrotic Syndrome Treatment Market Size, Share, Growth, Trends, and Forecast 20 …
July 2025 | By Shweta Raskar, Business Development Specialist at Prophecy Market Insights
Prophecy Market Insights has recently published a comprehensive research report on the Nephrotic Syndrome Treatment Market, offering in-depth insights into key growth dynamics, future opportunities, and competitive landscape shaping the market from 2025 to 2035. The report spans 145+ pages, delivering valuable intelligence for pharmaceutical companies, healthcare providers, investors, and policymakers.
📎 Get a Free Sample Report Here:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5788
🔑 Key…
Nephrotic Syndrome Market Outlook 2025-2034: Key Trends, Growth Drivers, and Mar …
How Are the key drivers contributing to the expansion of the nephrotic syndrome market?
The increasing incidence of kidney diseases is anticipated to drive the growth of the nephrotic syndrome market. Kidney diseases, which impair the kidneys' ability to filter waste from the blood, are rising due to factors like diabetes, hypertension, obesity, and aging populations. Nephrotic syndrome, which causes damage to the kidneys' glomeruli and impairs filtration, contributes to the…
Nephrotic Syndrome Treatment Market Size, Emerging Drugs, Market Outlook, and Co …
DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Nephrotic Syndrome Market by downloading the comprehensive report from DelveInsight @ Nephrotic Syndrome Therapeutics Market- https://www.delveinsight.com/sample-request/nephrotic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
Nephrotic Syndrome Diagnostics & Therapeutics Market Demand Analysis, Growth, Tr …
The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of around 5.6% during the forecast period (2024-2031). The key factor to drive the market growth includesthe increasing prevalence of diabetes that results in increased chances of nephrotic syndrome. For instance, In the European Union, approximately 32.3 million adults were diagnosed with diabetes in 2019, up from an estimated 16.8 million adults in 2000. In…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market - Transforming Kid …
Newark, New Castle, USA: The "Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market: https://www.growthplusreports.com/report/focal-segmental-glomerulosclerosis-fsgs-therapeutics-market/8837
This latest report…